-DOCSTART- -X- O
Surfactant -X- _ B-Intervention
protein -X- _ I-Intervention
D -X- _ I-Intervention
( -X- _ I-Intervention
SP-D -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
a -X- _ O
multimeric -X- _ O
collectin -X- _ O
that -X- _ O
is -X- _ O
involved -X- _ O
in -X- _ O
innate -X- _ O
immune -X- _ O
defense -X- _ O
and -X- _ O
expressed -X- _ O
in -X- _ O
pulmonary -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
non-pulmonary -X- _ O
, -X- _ O
epithelia. -X- _ O
SP-D -X- _ B-Intervention
exerts -X- _ O
antimicrobial -X- _ O
effects -X- _ O
and -X- _ O
dampens -X- _ O
inflammation -X- _ O
through -X- _ O
direct -X- _ O
microbial -X- _ O
interactions -X- _ O
and -X- _ O
modulation -X- _ O
of -X- _ O
host -X- _ O
cell -X- _ O
responses -X- _ O
via -X- _ O
a -X- _ O
series -X- _ O
of -X- _ O
cellular -X- _ O
receptors. -X- _ O
However -X- _ O
, -X- _ O
low -X- _ O
protein -X- _ O
concentrations -X- _ O
, -X- _ O
genetic -X- _ O
variation -X- _ O
, -X- _ O
biochemical -X- _ O
modification -X- _ O
, -X- _ O
and -X- _ O
proteolytic -X- _ O
breakdown -X- _ O
can -X- _ O
induce -X- _ O
decomposition -X- _ O
of -X- _ O
multimeric -X- _ O
SP-D -X- _ B-Intervention
into -X- _ O
low-molecular -X- _ O
weight -X- _ O
forms -X- _ O
, -X- _ O
which -X- _ O
may -X- _ O
induce -X- _ O
pro-inflammatory -X- _ O
SP-D -X- _ O
signaling. -X- _ O
Multimeric -X- _ O
SP-D -X- _ O
can -X- _ O
decompose -X- _ O
into -X- _ O
trimeric -X- _ O
SP-D -X- _ O
, -X- _ O
and -X- _ O
this -X- _ O
process -X- _ O
, -X- _ O
and -X- _ O
total -X- _ O
SP-D -X- _ O
levels -X- _ O
, -X- _ O
are -X- _ O
partly -X- _ O
determined -X- _ O
by -X- _ O
variation -X- _ O
within -X- _ O
the -X- _ O
SP-D -X- _ O
gene -X- _ O
, -X- _ O
SFTPD. -X- _ O
SP-D -X- _ O
has -X- _ O
been -X- _ O
implicated -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
respiratory -X- _ B-Patient
diseases -X- _ I-Patient
including -X- _ I-Patient
respiratory -X- _ I-Patient
distress -X- _ I-Patient
syndrome -X- _ I-Patient
, -X- _ I-Patient
bronchopulmonary -X- _ I-Patient
dysplasia -X- _ I-Patient
, -X- _ I-Patient
allergic -X- _ I-Patient
asthma -X- _ I-Patient
, -X- _ I-Patient
and -X- _ I-Patient
chronic -X- _ I-Patient
obstructive -X- _ I-Patient
pulmonary -X- _ I-Patient
disease. -X- _ I-Patient
Disease-induced -X- _ B-Outcome
breakdown -X- _ I-Outcome
or -X- _ I-Outcome
modifications -X- _ I-Outcome
of -X- _ I-Outcome
SP-D -X- _ I-Outcome
facilitate -X- _ I-Outcome
its -X- _ I-Outcome
systemic -X- _ I-Outcome
leakage -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
lung -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
circulatory -X- _ I-Outcome
SP-D -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
biomarker -X- _ I-Outcome
for -X- _ I-Outcome
lung -X- _ I-Outcome
injury. -X- _ I-Outcome
Moreover -X- _ O
, -X- _ O
studies -X- _ O
in -X- _ O
preclinical -X- _ O
animal -X- _ O
models -X- _ O
have -X- _ O
demonstrated -X- _ O
that -X- _ O
local -X- _ B-Outcome
pulmonary -X- _ I-Outcome
treatment -X- _ I-Outcome
with -X- _ I-Outcome
recombinant -X- _ I-Outcome
SP-D -X- _ I-Outcome
is -X- _ I-Outcome
beneficial -X- _ I-Outcome
in -X- _ I-Outcome
these -X- _ I-Outcome
diseases. -X- _ I-Outcome
In -X- _ O
recent -X- _ O
years -X- _ O
, -X- _ O
SP-D -X- _ B-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ I-Outcome
exert -X- _ I-Outcome
antimicrobial -X- _ I-Outcome
and -X- _ I-Outcome
anti-inflammatory -X- _ I-Outcome
effects -X- _ I-Outcome
in -X- _ I-Outcome
various -X- _ I-Outcome
non-pulmonary -X- _ I-Outcome
organs -X- _ I-Outcome
and -X- _ I-Outcome
to -X- _ I-Outcome
have -X- _ I-Outcome
effects -X- _ I-Outcome
on -X- _ I-Outcome
lipid -X- _ I-Outcome
metabolism -X- _ I-Outcome
and -X- _ I-Outcome
pro-inflammatory -X- _ I-Outcome
effects -X- _ I-Outcome
in -X- _ I-Outcome
vessel -X- _ I-Outcome
walls -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
enhance -X- _ I-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
atherosclerosis. -X- _ I-Outcome
A -X- _ O
common -X- _ O
SFTPD -X- _ O
polymorphism -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
atherosclerosis -X- _ O
and -X- _ O
diabetes -X- _ O
, -X- _ O
and -X- _ O
SP-D -X- _ B-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
metabolic -X- _ I-Outcome
disorders -X- _ I-Outcome
because -X- _ I-Outcome
of -X- _ I-Outcome
its -X- _ I-Outcome
effects -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
endothelium -X- _ I-Outcome
and -X- _ I-Outcome
adipocytes -X- _ I-Outcome
and -X- _ I-Outcome
its -X- _ I-Outcome
obesity-dampening -X- _ I-Outcome
properties. -X- _ I-Outcome
This -X- _ O
review -X- _ O
summarizes -X- _ O
and -X- _ O
discusses -X- _ O
the -X- _ O
reported -X- _ O
genetic -X- _ O
associations -X- _ O
of -X- _ O
SP-D -X- _ B-Intervention
with -X- _ O
disease -X- _ O
and -X- _ O
the -X- _ O
clinical -X- _ O
utility -X- _ O
of -X- _ O
circulating -X- _ O
SP-D -X- _ B-Intervention
for -X- _ O
respiratory -X- _ B-Patient
disease -X- _ I-Patient
prognosis. -X- _ I-Patient
Moreover -X- _ O
, -X- _ O
basic -X- _ O
research -X- _ O
on -X- _ O
the -X- _ O
mechanistic -X- _ O
links -X- _ O
between -X- _ O
SP-D -X- _ B-Intervention
and -X- _ O
respiratory -X- _ B-Patient
, -X- _ I-Patient
cardiovascular -X- _ I-Patient
, -X- _ I-Patient
and -X- _ I-Patient
metabolic -X- _ I-Patient
diseases -X- _ I-Patient
is -X- _ O
summarized. -X- _ O
Perspectives -X- _ O
on -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
SP-D -X- _ O
therapy -X- _ O
are -X- _ O
addressed -X- _ O
. -X- _ O

